Clinical trials: bipolar
Depression, Bipolar
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the…
- Trial name
- NCT00191399
- Testing
- Olanzapine, Fluoxetine
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder
The purpose of this study is to determine the safety and effectiveness of Depakote ER compared to placebo in the treatment of bipolar disorder, manic or mixed type in adults.
- Trial name
- NCT00060905
- Testing
- Divalproex Sodium (Depakote ER)
- Where
- 18 sites in United States
- Volunteers
- 370 people
- Sponsor
- Abbott
Bipolar Disorder
An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents
The purpose of this study is to determine the safety and effectiveness of Depakote ER (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar disorder, manic or mixed type in children and…
- Trial name
- NCT00067262
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Abbott
Bipolar Disorder
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs.
- Trial name
- NCT00071253
- Testing
- Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Abbott
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
This is a research study comparing the safety and efficacy of two active study medications for the treatment of bipolar I disorder.
- Trial name
- NCT00034580
- Testing
- olanzapine, risperidone
- Where
- 21 sites in United States
- Volunteers
- 326 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company